The chemical NMP as a potent BMP enhancer for bone tissue regeneration by San Miguel, B et al.
University of Zurich
Zurich Open Repository and Archive
Winterthurerstr. 190
CH-8057 Zurich
http://www.zora.uzh.ch
Year: 2009
The chemical NMP as a potent BMP enhancer for bone tissue
regeneration
San Miguel, B; Ghayor, C; Ehrbar, M; Jung, R E; Zwahlen, R A; Hortschansky, P;
Schmökel, H G; Weber, F E
San Miguel, B; Ghayor, C; Ehrbar, M; Jung, R E; Zwahlen, R A; Hortschansky, P; Schmökel, H G; Weber, F E
(2009). The chemical NMP as a potent BMP enhancer for bone tissue regeneration. Tissue Engineering Part A,
15(10):2955-2963.
Postprint available at:
http://www.zora.uzh.ch
Posted at the Zurich Open Repository and Archive, University of Zurich.
http://www.zora.uzh.ch
Originally published at:
Tissue Engineering Part A 2009, 15(10):2955-2963.
San Miguel, B; Ghayor, C; Ehrbar, M; Jung, R E; Zwahlen, R A; Hortschansky, P; Schmökel, H G; Weber, F E
(2009). The chemical NMP as a potent BMP enhancer for bone tissue regeneration. Tissue Engineering Part A,
15(10):2955-2963.
Postprint available at:
http://www.zora.uzh.ch
Posted at the Zurich Open Repository and Archive, University of Zurich.
http://www.zora.uzh.ch
Originally published at:
Tissue Engineering Part A 2009, 15(10):2955-2963.
 1
The chemical NMP as a potent BMP enhancer for bone tissue regeneration 
 
Running Title: NMP is a novel drug for bone regeneration 
 
Blanca San Miguel PhD1, Chafik Ghayor PhD1, Martin Ehrbar PhD1, Roland E. Jung 
DDS2, Roger A. Zwahlen MD,DDS1, Peter Hortschansky PhD3, Hugo G. Schmoekel 
PhD, MD vet.4, Franz E. Weber PhD1* 
 
1 Oral Biotechnology & Bioengineering University Hospital Zurich, Dept. of Cranio-
Maxillofacial Surgery, Frauenklinikstrasse 24, 8091 Zürich, Switzerland; 2Department 
of Fixed and Removable Prothodontics and Dental Material Science, University of 
Zurich, Switzerland; 4 Leibniz-Institut für Naturstoff-Forschung und Infektionsbiologie 
- Hans-Knöll-Institut (HKI), Jena, Germany, 4Great western Referrals, Shrivenham 
Road, Swindon SN1 2NR, UK 
 
BSM and CG have contributed equally to this work. 
 
* To whom correspondence should be addressed: Universitätsspital; Klinik für Kiefer- 
und Gesichtschirurgie; Frauenklinikstrasse 24, 8091 Zürich; Switzerland, Tel. +41 44 
255 5055, Fax +41 44 255 4179, e-mail:  franz.weber@zzmk.uzh.ch 
 
 
 
 
 
 2
Abstract: 
 
In medicine N-methylpyrrolidone (NMP) has a long track record as constituent in FDA 
approved medical devices and thus can be considered as safe and biological inactive 
small chemical. In the present study we report on the newly discovered 
pharmaceutical properties of NMP as it enhances bone regeneration in a rabbit 
calvarial defect model in vivo. At the cellular level, the pharmaceutical effect of NMP 
was confirmed, in particular, in combination with BMP-2, as NMP increased early and 
late markers for maturation of preosteoblasts and human bone marrow derived stem 
cells in vitro. When we used the multipotent cell line C2C12 lacking autologous BMP 
expression, NMP alone had no effect on alkaline phosphatase activity, a marker for 
osteogenic transdifferentiation. Nevertheless, in combination with low BMP-2-doses 
alkaline phosphatase activity was increased more than 8 fold. Thus, the 
pharmaceutical NMP mode of action is that of an enhancer of BMP activity. The 
dependency of the effects of NMP on BMP was confirmed in preosteoblasts as 
noggin, an extracellular BMP-inhibitor, suppressed NMP-induced increase in early 
markers for osteoblast maturation in vitro. At the molecular level, NMP was shown to 
have no effect on the binding of BMP-2 to the ectodomain of the high affinity BMP 
receptor IA. However, NMP further increased the phosphorylation of p38 and 
Smad1,5,8 induced by BMP-2. Thus, the small chemical NMP enhances BMP activity 
by increasing the kinase activity of the BMP receptor complex for Smad1,5,8 and p38 
and could be employed as a potent drug for bone tissue regeneration and 
engineering. 
 
Keywords:  small chemical, BMP, Smad, p38, osteoblast, BMP enhancer 
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Introduction 
In bone tissue engineering BMPs are certainly the most potent factors to induce bone 
formation, since they can induce bone formation even at ectopic sites (1). At the 
cellular level, binding of BMP to a high affinity BMP receptor type I homodimer 
(BMPR I) is followed by the recruitment of a low affinity BMPR II homodimer. Due to 
the close proximity, the constitutively active BMPR II then phosphorylates and 
activates BMPR I in the BMP receptor complex (2). BMPR I of the BMP receptor 
complex, in turn, phosphorylates Smad proteins, causing their activation and 
translocation to the nucleus, where they regulate the transcription of BMP-responsive 
genes (3). Beyond Smad phosphorylation the formation of the active BMP receptor 
complex also affects the MAPK pathways by BMP-receptor mediated 
phosphorylation of p38 (4). Of so far unknown biological relevance is the association 
of a number of additional proteins with the intracellular portion of the BMP receptor 
complex (5, 6).  
Extracellular BMP binding to its receptor and BMP signaling are regulated by locally 
secreted BMP antagonists. One of the best characterized BMP antagonists is noggin, 
which was identified as a dorsalizing factor produced by Spemann’s organizer during 
early embryogenesis. Noggin exerts its bioactivity by high affinity binding to 
extracellular BMPs and blocking their binding to BMP receptors (7, 8). 
With the cloning, expression, and mass production of human recombinant BMPs very 
powerful growth and differentiation factors towards the osteogenic lineage had been 
developed up to the level of clinical application. However, the first clinical trials 
showed that milligram doses of BMP-2 were required (9). Therefore, BMP-
presentation and release kinetics, mainly determined by the delivery system, have to 
be optimized for an efficient clinical application of BMPs (10-12).  
Another strategy to decrease the BMP dose in clinical applications is to combine the 
cytokine with enhancers of BMP activity. Ideally, an enhancer should be a small 
molecule, easily applicable to the carrier materials and able to increase the activity of 
the therapeutic protein. In the future, enhancers might become novel tools to tune 
therapeutic molecules such as BMPs. In conjunction with bone tissue engineering, 
such enhancers could either reduce or substitute for the clinical application of BMPs.  
Recently we reported on the application of BMP-2 in conjunction with guided bone 
regeneration (GBR) (13). GBR is a clinically well-documented and successful 
procedure in dental implantology (14 59). It is based on the placement of a 
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membrane over the defect to create a compartment where bone can regenerate 
without competition to other faster growing tissues. Here we report on the 
unexpected finding that a NMP releasing GBR membrane induced an acceleration of 
bone regeneration in a rabbit calvarial defect model. Since this newly discovered 
pharmaceutical aspect of NMP to serve as accelerator of bone regeneration could 
prove useful for bone repair and bone tissue engineering, we started to characterize 
the bioactivity of NMP in more detail.  
 
Methods 
Reagents, guided bone regeneration membranes and antibodies. N-methyl 
pyrrolidone (NMP) was purchased from Sigma-Aldrich (St. Louis, MO, USA). The 
biodegradable woven flexible guided bone regeneration membrane OsseoQuest was 
purchased from Gore (Saint Guenault, France) and the solid rigid InionGTR 
membrane and NMP were obtained from Inion OY (Tampere, Finland). Polyclonal 
anti-p38, anti-α-actinin, anti-ERK1/2, anti-pERK1/2, anti-pp38, anti-pSmad1/5/8 were 
obtained from Cell signaling (Cell signaling Technology, MA, USA).  
 
Animal testing for GBR. We generated a GBR model in rabbits by drilling 4x6 mm 
diameter defects into the calvarial bones and placed membranes on each side of the 
defect to mimic a GBR situation. Membranes were used as recommended by the 
manufacturer. The InionGTR membrane was used as solid rigid membrane without 
NMP pretreatment or as solid flexible membrane following NMP treatment. In brief, 
the solid rigid InionGTR membranes were submerged in NMP for 30 seconds, air 
dried for 15 minutes, and then washed in PBS to remove NMP from the outside of the 
membrane. During this procedure, the initially rigid membrane became flexible (15). 
Four weeks after operation the animals were sacrificed, the samples were embedded 
for histology, and analyzed for bone regeneration as previously reported (16). All 
studies were approved by the ethics committee of the Canton of Zurich and the 
University of Zurich.  
 
Cell cultures. C2C12 and MC3T3-E1 clone 4 were purchased from American Type 
Culture Collection (ATCC, Manassas, USA) via the European distributor ECACC 
(Salisbury, UK). The osteoblastic cell line MC3T3-E1 has been established from a 
C57BL/6 mouse calvaria and selected on the basis of high alkaline phosphatase 
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(ALP) activity in the resting state. These cells have the capacity to differentiate into 
osteoblasts and osteocytes and have been shown to form calcified bone tissue in 
vitro. C2C12 cells are pluripotent myogenic cells able to transdifferentiate in a variety 
of tissues like bone and adipose tissue. Therefore, they are often used as a model for 
mesenchymal stem cells (17). Cells were cultured in Dulbecco’s modified Eagle’s 
medium (DMEM) (C2C12) or alpha-minimal essential medium (MC3T3-E1) 
supplemented with 10% fetal calf serum and antibiotics (100 U/ml penicillin G and 
100 mg/ml streptomycin). Cells were trypsinized and passaged every 2–3 days, and 
cultures were never allowed to become confluent. All cells were grown at 37°C in 
humidified air mixed with 5% CO2.  
 
Human bone marrow derived stromal cells. The human bone marrow derived 
stromal cells were a gift from Dr. Lorenz Meinel (ETH Zurich, Switzerland). They had 
been isolated by density gradient centrifugation from whole bone marrow (25 cm2 
harvests) obtained from Clonetics (Santa Rosa, CA) as described in (18). Briefly, 
bone marrow suspensions were overlaid onto a polysucrose gradient (δ = 1.077 
g/cm3) and centrifuged at 800 g for 30 min at room temperature. After lysis of the 
remaining red blood cells the cell layer was pelleted, resuspended in expansions 
medium (DMEM, 10% fetal bovine serum, 1 ng/ml basic fibroblast growth factor), and 
seeded at a density of 5x104 cells/cm2. The adherent cells were allowed to reach 
80% confluency. The second passage cells were frozen and used for experiments. 
All cell batches were characterized with respect to expression of specific cell markers 
(18), and for their ability to differentiate into chondrogenic and osteogenic lineages. 
Osteogenesis was studied in expansion medium supplemented with 50 µg/ml 
ascorbic acid, and 7 mM ß-glycerolphosphate (Sigma-Aldrich, St. Louis, MO, USA). 
 
ALP activity assay. Alkaline phosphatase activity (ALP) was measured as a marker 
of osteoblastic differentiation in MC3T3-E1 and C2C12 cells. Cells were seeded at a 
density of 5×104 cells/cm2 in 6 or 24-well plates (n = 3 per group). Treatment with 
NMP, BMP-2, and noggin diluted in the tissue culture medium started 5 h after 
seeding, and incubation was continued for 6 more days. Human recombinant BMP-2 
(BMP-2) used in this study is produced in our laboratory (19) to a quality that even 
allowes its clinical application (13). Noggin was a gift of Peter Hortschansky (Jena, 
Germany) and was applied at 1µg/ml (20). After 6 days of incubation, media was 
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removed, and cells were washed with phosphate buffered saline (PBS) and then 
scrapped in 0.56M 2-amino-2-methyl-1-propanol, pH 10.5. The pellets were then 
homogenized for 10 seconds. After centrifugation, the supernatant was collected and 
tested for ALP activity using p-nitrophenylphosphate (Sigma, Aldrich; St. Louis, MO, 
USA) as a substrate (20). The protein content of the lysates was determined using 
Bradford protein assay reagent (Bio-Rad laboratories; Hercules, CA; USA). 
Experiments were performed independently in triplicate.  
 
Calcium deposition by preosteoblastic cells 
MC3T3-E1 cells were maintained in an alpha-modified Minimum Essential Medium 
(Life Technologies, Inc., Grand Island, NY) containing 10 % fetal calf serum (Life 
Technologies, Inc.), and 50 µg/ml gentamycin were plated at a density of 30,000 
cells/cm2 in 6 well plates. Starting at 80% confluency (normally day 3 after plating), 
the culture medium was supplemented with 50 µg/ml ascorbic acid, 10 mM β-
glycerophosphate and the different molecules. Media change, as well as NMP and/or 
BMP-2 additions were performed once a week and calcium deposition was 
determined after 4 weeks in culture. For Alizarin red staining of calcium, cultured 
MC3T3 or human bone marrow derived stromal cells were washed once with PBS 
and fixed for 1 hour in 70% ethyl alcohol. After rinsing the cells with water, 4 ml of an 
Alizarin red solution (40 mM, pH 4.2) were added and the cells were stained for 10 
minutes. Non-specific staining was removed by several washes with water and the 
stained wells were photographed.  
 
Quantitative RT-PCR. mRNA was isolated from MC3T3 cells after six days of 
stimulation using the RNeasy Mini Kit (Qiagen, Hilden, Germany). After performing 
the reverse transcription reaction (1st strand cDNA Synthesis Kit for RT-PCR, Roche, 
Mannheim, Germany), 1st strand cDNA samples were quantified by serial dilutions in 
a Light Cycler system (LightCycler ® 2.0 Real-Time PCR System, Roche, Mannheim, 
Germany) by SYBR green (Fast start DNA master SYBR Green 1, Roche, 
Mannheim, Germany) and normalized to GAPDH and control samples, respectively. 
The conditions for the 42 cycles were: denaturation for 15 seconds at 95°C, 
annealing for 10 seconds at 58°C for GAPDH, 60°C for osterix, and 61° for 
osteocalcin, followed by extension for 20 seconds at 72°C. The following primers 
were used: Osterix for: 5'-CCCCTGCTCCTTCTAGGC-3', Osterix rev: 5'-
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CCGTCAACGACGTTATGC-3', Osteocalcin for: 5'-ACAAGTCCCACACAGC-AGCTT-
3', Osteocalcin rev: 5'-GCCGGAGTCTGTTCACTACCT-3', GAPDH for: 5'- 
AACGACCCCTTCATTGAC-3', GAPDH rev: 5'-TCCACGACATACTCAGCA-3'.  
 
Western blotting analysis. MC3T3-E1 cells treated with the different compounds 
were rapidly frozen in liquid nitrogen and stored at −80°C for further analysis. In 
experiments aimed at testing for the effect of NMP on p38, cells were made 
quiescent for stress and mitogen-activated protein kinase (MAPK) by switching to 1% 
foetal calf serum 24 h before and during the study (21). Cells were lysed at 4°C in 
lysis buffer containing 50 mM Tris (pH 7.4), 150 mM NaCl, 1 mM 
phenylmethylsulfonyl fluoride, supplemented with a protease inhibitor (Protease 
Inhibitor Cocktail Set III, Calbiochem), 1% Nonidet P-40, 1% sodium deoxycholate, 
and 0.1% (w/v) sodium dodecyl sulphate (SDS) for 10 min. Lysates were then 
cleared by centrifugation at 6000 × g for 30 min. Proteins were fractionated onto a 
12% SDS-PAGE gel, transferred to Immobilon P membranes (Millipore, Zug, 
Switzerland) and immunoblotted with specific antibodies (22, 23). Detection was 
performed using peroxidase-coupled secondary antibody, enhanced 
chemiluminescence reaction (Amersham ECL™ Western Blotting Detection 
Reagents, GE Healthcare Europe GmbH Otelfingen, Switzerland) and visualization 
by autoradiography. Membranes that were reprobed had been stripped in stripping 
buffer (62.5 mM Tris-HCl pH 6.8, 2% (w/v) SDS, 100 mM β-mercaptoethanol) 
according to the manufacturer's protocol (Millipore, Zug, Switzerland). 
 
Biosensor interaction analysis. The BIA2000 system (BIAcore, GE Healthcare, 
Europe Otelfingen, Switzerland) was used to record the binding of BMP-2 to 
immobilized receptor ectodomains at different NMP concentrations. The biotinylated 
receptor proteins were fixed separately to streptavidin-coated matrix of biosensor 
CM5 in flow cell 2, 3, and 4 at a density of 190 resonance units (RU) corresponding 
to 190 pg of protein (~14.5 fmol of receptor) per mm2. 0.23 to 7.2 µg/ml BMP-2 (6.25-
200 nM) in 10 mM HEPES pH 7.4, 500 mM NaCl, 3.4 mM EDTA, 0.005% surfactant 
P20 were perfused over all 4 flow cell in series at a flow rate of 10 µl/min at 25°C, 
and sensograms were recorded at a data sampling rate of 2.5 Hz. The association 
period was 5 min and the dissociation period was set to 3 min. Free receptors were 
regenerated by perfusion with 0.1 M acetic acid, 1 M NaCl for 2 min. A background 
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sensogram (streptavidin control) was subtracted from the sensograms obtained in the 
flow cells with attached BMPR-IA. The different sensograms were evaluated 
according the fitting routine 2 provided by BIA evaluation 2.2.4 software (BIAcore). 
The equilibrium binding of rhBMP-2 to the ectodomain of BMPR-IA at steady state 
was determined in triplicate at 6 different concentrations of BMP-2 to obtain kD 
values. 
 
Statistical analysis. The software SPSS 10 was used to calculate the mean values, 
standard deviation and standard error of the measurement. Unless otherwise 
indicated, standard deviation is given. For statistical analysis Student’s t-test was 
applied after a normal deviation was confirmed by Kolmogorov-Smirnov and Shapiro-
Wilks-test. 
 
 
Results 
The presence of NMP in a biodegradable GBR membrane accelerates bone 
regeneration in vivo. 
In the course of the development of a biodegradable guided bone regeneration 
(GBR) membrane we performed an in vivo study to screen several membrane 
prototypes.  The drawback in using biodegradable polylactide/polyglycolide-based 
membranes, such as the InionGTR membrane, is their inherent rigidity, 
compromising their applicability in the clinic. One strategy to overcome this problem 
was to use NMP as plasticizer to generate more flexible membranes (15). 
Interestingly, in the initial screening the best performing membranes all contained 
NMP. To further investigate this finding, we carried out another animal study with 8 
rabbits (Fig 1), comparing bone regeneration in untreated defects to defects treated 
with a solid polylactide/polyglycolide-based membrane with and without NMP 
(InionGTR), and a woven polylactide/polyglycolide-based membrane (OsseoQuest). 
The latter was included as biodegradable flexible control membrane, to discriminate 
the plasticizing aspect of NMP from its pharmaceutical one. When left untreated, 
bone regeneration within the model system was 28.42 ± 3.18 (s.e.m.) %, while the 
application of a flexible woven membrane (OsseoQuest) increased bone 
regeneration to 57.02 ± 9.20 (s.e.m.) %, and application of solid rigid membranes 
yielded 49.31 ± 8.75 (s.e.m.) % bone regeneration. The difference in bone 
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regeneration facilitated by the flexible woven and rigid solid membrane was not 
significant (P=0.456) suggesting that an increase in flexibility of the membrane has 
no positive effect on bone regeneration in this model system. When the same solid 
membrane was loaded with NMP, bone regeneration increased to 79.17 ± 5.61 
(s.e.m) % (Fig. 1). The increase in bone regeneration was significantly higher, than 
with the non-treated rigid solid (P < 0.016; n = 8), or flexible woven membrane (P < 
0.021; n = 8), suggesting that NMP not only serves as softener of the rigid solid 
membrane but also enhances bone regeneration.  
 
In preosteoblasts, NMP increases early markers for bone formation in a 
concentration dependent fashion and this effect requires autologous BMP. 
To study the biological effect of NMP in more detail, we used the MC3T3-E1 cell line 
as a model for preosteoblastic cells in vitro. In bone, autologous BMP is deposited in 
the extracellular matrix. In vitro culture of MC3T3-E1 preosteoblastic cells can be 
used to model the situation in vivo, as they mature to osteoblasts dependent on 
BMPs, which they secrete and deposit into the extracellular matrix. When we 
subjected MC3T3-E1 cells to NMP, alkaline phosphatase (ALP) activity, an early 
maker for bone formation (Fig. 2a), showed a concentration dependent increase.  
To test whether the bioactivity of NMP is dependent on autologous BMP, we 
employed the BMP-antagonist noggin, to bind and neutralize autologous BMP (7, 
24). Upon noggin application, ALP activity decreased to 51.77 ± 6.39 % of the control 
level and could not be restored by NMP application (64.66 ± 11.89 %; P < 0.125; n = 
9). Thus, the effect of NMP on preosteoblasts depends on the presence of 
autologous BMP. 
 
Effect of NMP/BMP-2 combinations on preosteoblastic cells. 
To further investigate the interplay between NMP and BMP in bone formation and 
repair in greater detail, preosteoblastic cells were treated with combinations of NMP 
and BMP-2. At 1 µg/ml BMP-2 and increasing concentrations of NMP, ALP activity 
increase was much higher than the effect of treatment with BMP-2 or NMP alone 
(Fig. 2a). A late marker for osteoblast maturation is the mineralization of the 
extracellular matrix. When we exposed preosteoblasts to increasing concentrations of 
NMP, calcium deposition was not affected (Fig. 2b). In combination with 1 µg/ml 
BMP-2, however, rising NMP concentrations (Fig. 2b) markedly increased calcium 
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deposition, when compared to BMP-2 or NMP treatment alone. Thus NMP has an 
enhancing effect with BMP-2 treatment both on early and late markers of osteoblast 
maturation. Next we performed real time quantitative PCR to determine mRNA levels 
of markers of bone formation in preosteoblastic cells. Osteocalcin mRNA, a late 
marker for bone formation, increased 19.80 ± 0.22 fold in preosteoblasts treated with 
5 mM NMP and 1 µg/ml BMP-2, 1.26 ± 0.09 fold with 5 mM NMP and 14.73 ± 1.15 
fold with 1 µg/ml BMP-2 compared to control untreated cells (Fig. 2c). The enhancing 
effect was also detectable for the mRNA content of the late bone specific 
transcription factor osterix II (25). mRNA levels of osteocalcin were increased 7.70 ± 
0.41 fold in preosteoblasts treated with 5 mM NMP and 1 µg/ml BMP-2, 1.38 ± 0.09 
fold with 5 mM NMP, and 4.31 ± 0.21 fold with 1 µg/ml BMP-2 compared to control 
untreated cells (Fig. 2d).  
 
NMP is an enhancer of BMP-2 activity 
To discriminate between enhancing and synergistic effect of NMP/BMP-2 
combinations we used the pluripotent mesenchymal cell line C2C12. Unlike MC3T3-
E1 cells, C2C12 cells do not express BMPs. However, exposure of C2C12 cells to 
BMP is known to convert these cells from the myoblastic to the osteoblastic lineage. 
The conversion in response to BMP treatment can be monitored by the BMP 
concentration dependent increase in ALP activity (26). In the absence of NMP, an 
increase in ALP activity was induced starting at a BMP-2 concentration of 100 ng/ml 
BMP-2 (Fig. 3a). In the absence of BMP, increasing NMP concentrations ranging 
from 1-5 mM had no effect on ALP activity. At 50 ng/ml BMP-2, ALP activity did not 
increase compared to untreated cells. However, in combination with 5 mM NMP, ALP 
activity was significantly increased (P=0.04). This increase was even more 
pronounced at higher BMP-2 concentrations (Fig. 3b).  The maximum enhancing 
effect of 5 mM NMP was seen at 100 ng/ml BMP-2 with 8.43 ± 1.51 fold increase, 
declining to a 1.91 ± 1.51 fold increase at 800 ng/ml BMP-2, and remaining in this 
fold range up to a BMP-2 concentration of 1200 ng/ml. To show the clinical relevance 
of our finding we tested the enhancing effect of 5 mM NMP and 100 ng/ml BMP-2 on 
human bone marrow derived stromal cells. When we exposed primary human bone 
marrow stromal cells to either 100 ng/ml BMP or 5 mM NMP alone (Fig. 4 a, b) 
calcium deposition was not induced. However, in the presence of 5 mM NMP the 
activity of 100 ng/ml BMP-2 was enhanced to an extent that nodule formation 
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occurred (Fig.4a,b) and calcium deposition was significantly increased (P<0.001) (Fig 
4c).  
 
NMP enhances the kinase activity of the BMP receptor complex for Smads and 
p38. 
To explore the mechanisms by which NMP enhances BMP-2 activity, we first studied 
the effect of NMP on BMP-2 binding to the extracellular portion of the BMP receptor-
1A (BMPR-1A). BMPR-1A high affinity receptor for BMP was chosen because type II 
receptors make only a minor contribution to the affinity of BMP-2 for the receptor on 
whole cells (2). The binding of BMP-2 to the ectodomain of the recombinant BMPR-
1A with varying concentrations of NMP was analyzed using biosensor interaction 
analysis (27). With the NMP concentrations tested (0 - 100 mM) no change in the 
affinity of BMP-2 to the BMPR-1A ectodomain was observed (Fig. 5a). The apparent 
KD value with increasing BMP-2 concentrations (6.25 to 200 nM) was 1.67 nM in the 
absence and 1.63 nM in the presence of 50 mM NMP (Fig. 5b).  
Next, we looked at the effect of NMP on the kinase activity of the intracellular portion 
of BMPR I in preosteoblastic cells. In the first 15 minutes following application of 5 
mM NMP and 1 µg/ml BMP-2 the phosphorylation of BMPR-specific Smad proteins 
was induced (Fig. 5c). However, after 15 minutes any further increase was 
undetectable. In addition to Smad phosphorylation, BMP also signals via p38 
phosphorylation (4), which can only be studied at low serum concentrations. When 
the cells were treated under this serum conditions with 5 mM NMP and 1 µg/ml BMP-
2, Smad and p38 phosphorylation increased after one hour, suggesting a longer 
lasting effect of NMP on BMP signaling (Fig. 5d). 
 
Discussion 
The starting point of this study was the discovery that NMP, initially used as 
plasticizer for a rigid solid polylactide/polyglycolide-based membrane, also enhances 
bone regeneration by a factor of two in a calvarial bone regeneration model in vivo 
(Fig.1).  
Following this discovery of a potential pharmaceutical effect of NMP made in an in 
vivo model system with relevance to the clinical situation we took a step back and 
started to characterize the bioactivity of NMP in greater detail.  
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The enhancing effect of NMP suggested by the calvarial defect model was confirmed 
in preosteoblastic cells of murine origin (MC3T3-E1), where NMP mediated a 
concentration-dependent increase in ALP activity, an early bone marker (Fig. 2a). 
Next, we showed that NMP action needs endogenous BMP, as addition of the BMP 
binding and neutralizing BMP antagonist noggin reduced the effect of NMP 
substantially. Next we looked at the effect of NMP/BMP-2 combinations. In the 
preosteoblastic cell line MC3T3-E1, NMP enhanced BMP activity as illustrated by 
higher ALP activity, mineral deposition, osteocalcin transcription, and osterix 
transcription levels above the BMP only values (Fig.2). Therefore, the effect of NMP 
on preosteoblasts can be linked to the BMP pathway.  
To discriminate between enhancing and synergistic effect of NMP and BMP-2 (as 
reviewed in (28)) we employed the multipotent C2C12 cells which lack autologous 
BMP expression. The results showed that NMP alone is not osteogenic, because it is 
insufficient to direct C2C12 cells towards the osteoblastic lineage. In combination 
with BMP-2, however, the osteogenic effect of BMP-2 determined by the increase in 
ALP activity was markedly enhanced by NMP (Fig. 3b). Even BMP-2 concentrations 
as low as 50 ng/ml, normally not able to convert the fate of C2C12 cells into the 
osteogenic lineage, are sufficient to increase ALP activity when applied in 
combination with 5mM NMP. To show the clinical relevance of our finding, a low 
BMP-2 concentration of 100 ng/ml was chosen and applied to human derived bone 
marrow stromal cells. In the absence of 5 mM NMP mineral deposition was not 
induced by 100 ng/ml BMP-2, but in combination with 5 mM NMP mineral deposition 
was induced. Therefore, the enhancing effect of NMP at low BMP-2 concentrations is 
also evident with human bone marrow derived stromal cells (Fig.4), which is a 
clinically used source for multipotent adult mesenchymal stem cells (29). In essence, 
adult human mesenchymal stem cells exposed to suboptimal BMP-2 dosages are 
guided towards the osteogenic lineage in the presence of NMP. Thus, NMP is an 
enhancer of the osteogenic effect of BMP-2 and its application in combination with 
BMP-2 could, potentially, decrease BMP-2 dosages needed for bone regeneration 
and bone tissue engineering approaches in medicine. To make this vision come true, 
additional studies and the development of an optimal dual delivery device for BMP-2 
and NMP are needed. For smaller bone defects, normally not treated with BMPs, the 
enhancing effect of NMP on the autologous BMP deposited in bone is able to 
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accelerate bone healing as illustrated in vivo in the calvarial defect model (Fig. 1). 
Therefore NMP alone is suitable to enhance bone regeneration at orthotopic sites.  
At the molecular level, a BMP receptor complex is needed for BMP signaling. 
Extracellular BMP binds with high affinity to BMPR I which contributes the majority to 
the affinity of BMP-2 for the receptor on whole cells (2). Our results show that the 
binding of BMP-2 to the ectodomain of the BMPR IA is not affected by NMP (Fig 5a, 
b). However, in the evanescent field based BIAcore system, only the binding of single 
BMP-2 dimers to single BMPR IA ectodomains were determined, leaving possible 
contributions of the second BMPR IA and/or the two BMPR II receptor ectodomains 
to the binding affinity out. Therefore, an effect of NMP on the binding of BMP-2 to the 
whole extracellular part of the BMP receptor complex can not be totally ruled out, 
since in vivo it involves a complex composed of two BMPR I molecules, two BMPR II 
molecules, and one BMP-2 dimer. Another open question is the biological effect of 
metabolites of NMP on receptor binding. In man and rats the main metabolite of 
orally administered NMP is 5-hydroxy-N-methylpyrrolidone and it is excreted in urine 
(30). In humans, a major metabolic pathway from 5-hydroxy-N-methylpyrrolidone, to 
N-methylsuccinimide to 2-hydroxy-N-methylsuccinimide has been suggested (31). 
However, a biological effect of any of these metabolites has not been reported.  
The elements of the BMP pathway just downstream of the BMP receptors are Smads 
and p38 (32, 33). The combined application of BMP-2 and NMP substantially 
increased Smad phosphorylation at five minutes following NMP application (Fig. 5c) 
and the effect continued for more than an hour at low serum concentration for Smad 
and p38 phosphorylation (Fig. 5d). This series of experiments supports the 
enhancing mode of NMP on the BMP-2 activity, since NMP alone has a limited effect 
on the pathways involved in BMP signaling, but in combination with BMP-2, Smad 
phosphorylation is enhanced within minutes. Thus, NMP enhances the kinase activity 
of the BMPR I in the BMP receptor complex, which is responsible for Smad and p38 
phosphorylation in a way that does not involve protein synthesis.  
The most important modulator of BMP initial signaling is BMPRII (34) with its 
extended intracellular domain, known to interact with a variety of proteins comprising 
MAP kinases and PKC (6). Since the affinity of BMP-2 to the high affinity ectodomain 
of the receptor is NMP-independent (Fig 5a, b), but the initial BMP signal for Smad 
and p38 phosphorylation is increased under the influence of NMP, these data 
suggest that NMP acts most likely at the level of the intracellular portion of the BMP 
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receptor complex. Intracellular, the receptor complex is associated with several 
proteins (6) including c-kit (5) and most likely additional, so far unrecognized 
elements. One could speculate that the enhancing effect of NMP on BMP activity 
derives from a direct binding of NMP to the receptor or receptor associated proteins 
as has been shown for ethanol (35) or by interaction of NMP with membranes due to 
the plasticizing potential of NMP. The latter could perturb the curvature of 
membranes, receptor associated lipid rafts, or the spatial arrangement of membrane 
proteins and by doing so, enhancing the kinase activity of BMPRI for Smads and p38. 
Due to the complexity of these possible effects additional work is needed to pinpoint 
the direct target of NMP in the BMP receptor complex or its membranous 
environment. 
More than 50,000 metric tons of NMP are produced and used per year, mainly for 
cleaning purposes but also for plastic engineering and FDA-approved medical 
devices. Despite this broad use of NMP, nothing has yet been known about its 
enhancing effect on the BMP pathway essential during early and late developmental 
stages but also later on in life. Thus, our results highlight the need for a better 
understanding, beyond toxic and carcinogenic aspects, of the effect of industrial 
chemicals on biological systems. In the case of NMP a thorough investigation 
identified a novel, locally-applicable drug for bone repair, accelerated bone 
regeneration or potentially even for bone tissue engineering applications in 
combination with human recombinant BMP. In the clinic, NMP could prove useful as 
single drug for the treatment of small bone defects. In combination with human 
recombinant BMPs, NMP could serve as enhancer of BMP activity to treat critical 
size defects with much lower, and thus safer, and less expensive BMP dosages.  
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Figure legends: 
 
Figure 1. NMP enhances bone regeneration in vivo. 
Subcritical size defects were generated in calvarial bones of 8 rabbits and treated 
either with a solid rigid membrane, a woven flexible membrane, a solid NMP/flexible 
membrane, or left untreated. After four weeks bone regeneration within the defect 
was evaluated based on the middle cross sections (upper panel, defect area is 
indicated, scale of 400 µm is indicated). Histomorphometrical analysis (lower panel) 
revealed a significant increase in bone regeneration when the solid membrane 
contained NMP compared to the same membrane without NMP (P=0.016). The 
NMP-induced increase in flexibility of the solid membrane had no influence on bone 
regeneration in this model system as the solid rigid and the woven flexible 
membranes performed equally well. Histomorphometrical results are displayed (lower 
panel) as box-plots ranging from the 25th (lower quartile) to the 75th (upper quartile) 
percentile including the median and whiskers showing the minimum and maximum 
values. The Goldner Trichrome treated sections stain bone in green (upper panel). 
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Figure 2. Enhancing effect of NMP on the maturation of preosteoblastic cells.  
(a) In preosteoblastic cells, application of increasing amounts of NMP lead to an 
increase in ALP activity both with and without the addition of BMP-2 (■ no additional 
BMP; ♦ 1µg/ml BMP-2). Note the step in the y-axis.  (b) The enhancing effect on 
maturation was also seen for the mineral deposition of BMP-2 treated preosteoblastic 
cells, determined by Alizarin-red staining. At the molecular level the treatment of 
MC3T3-E1 cells with 5 mM NMP and  1µg/ml BMP-2 significantly increased the 
mRNA content of the late bone marker osteocalcin (c), as well as the mRNA levels of 
the bone specific late transcription factor osterix (d) (Student’s t-test, P provided, n = 
6). 
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Figure 3. NMP is an enhancer of BMP activity.  
(a) In multipotent C2C12 cells, which in contrast to MC3T3-E1 cells do not produce 
autologous BMP, increasing amounts of NMP had no effect on ALP activity. C2C12 
cells stimulated by increasing amounts of BMP-2 (50, 100, 150, 200, 400 ng/ml) 
showed a concentration dependent increase in ALP activity. Addition of NMP to 
BMP-2 treated cells further increased ALP activity dependent on NMP concentration. 
(b) With different BMP-2 concentrations, NMP-induced increase in ALP activity 
ranged from 1.9 to 8.3 fold. The most pronounced effect was in the range between 
50 and 200 ng/ml BMP-2.  
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Figure 4. Effect of a low BMP dosage and NMP and their combination on human 
bone marrow derived stromal cells. Human derived bone marrow stromal cells were 
exposed either to 5 mM NMP, 100 ng/ml BMP-2 or the combination thereof. After 5 
weeks of exposure, the cells were stained with alizarin-red. a) A close inspection of 
the plates revealed, that only the combination of 5 mM NMP and 100 ng/ml BMP 
induced the formation of calcified nodules. b) Overview of the plates. c) The visual 
appearance of the results was confirmed quantitatively via the content of bound 
calcium per well (Student’s t-test, P provided, n = 5).   
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Figure 5. Effect of NMP on BMP signaling.  
(a) The interaction of BMP-2 with BMPR-IA receptor ectodomain was determined at 
increasing NMP concentrations. The affinity to the BMPR-IA receptor ectodomain did 
not change within a range of 0-100 mM NMP. (b) Equilibrium binding at increasing 
concentrations of BMP-2 in the presence and absence of 50 mM NMP is shown. 
Over a range of 6.3 to 200 nM BMP-2 (0.23 to 7.2 µg/ml BMP-2), NMP concentration 
of 50 mM did not affect the binding of BMP to the receptor ectodomain. All points 
were measured in triplicate. (c) Preosteoblastic cells treated with 5 mM NMP and 1 
µg/ml BMP-2 show a massive increase in phosphorylated Smad (1, 5, 8) at the 5 
minutes time point. After 15 minutes the phospho-Smad 1,5,8 content of BMP-2 
stimulated and combination of both NMP (5mM) and BMP-2 (1 µg/ml) stimulated 
cells had leveled off. α-actinin is given as loading control. (d) At low serum 
concentration (1%), required to see an effect of BMP treatment on p38 
phosphorylation, the enhancing effect of 5 mM NMP on 1 µg/ml BMP-2-induced 
Smad phosphorylation was seen even after 60 minutes. In addition, phospho-p38 
was markedly increased. In the case of Erk, 5 mM NMP and 1 µg/ml BMP-2 induced 
phosphorylation at 5 minutes but showed no effect after 60 minutes. p38 and Erk are 
given as a loading control. 
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